Efficacy and safety by cytogenetic risk status: Phase 3 study (ASPIRE) of carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma

Authors
Publication date
1 January 2016
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens

    redirect
    oaioai:lib.uoa.gr:uoadl:2952527
    Last time updated on 10/02/2023

    Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens

    redirect
    oaioai:lib.uoa.gr:uoadl:2954681
    Last time updated on 10/02/2023